Literature DB >> 15662369

Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii.

Julio Aliberti1.   

Abstract

Hosts that are infected with Toxoplasma gondii must mount a powerful immune response to contain dissemination of the parasite and to prevent mortality. After parasite proliferation has been contained by interferon-gamma-dependent responses, the onset of the chronic phase of infection is characterized by continuous cell-mediated immunity. Such potent responses are kept under tight control by a class of anti-inflammatory eicosanoid, the lipoxins. Here, we review such immune-containment strategies from the perspective of the host, which attempts to keep pro-inflammatory responses under control during chronic disease, as well as from the perspective of the pathogen, which hijacks the lipoxygenase machinery of the host for its own advantage, probably as an immune-escape mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15662369     DOI: 10.1038/nri1547

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  44 in total

1.  Toxoplasma gondii cyclophilin 18 regulates the proliferation and migration of murine macrophages and spleen cells.

Authors:  Hany M Ibrahim; Xuenan Xuan; Yoshifumi Nishikawa
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

2.  Toxoplasma gondii prevents neuron degeneration by interferon-gamma-activated microglia in a mechanism involving inhibition of inducible nitric oxide synthase and transforming growth factor-beta1 production by infected microglia.

Authors:  Claudia Rozenfeld; Rodrigo Martinez; Sérgio Seabra; Celso Sant'anna; J Gabriel R Gonçalves; Marcelo Bozza; Vivaldo Moura-Neto; Wanderley De Souza
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

3.  NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells.

Authors:  William H Witola; Ernest Mui; Aubrey Hargrave; Susan Liu; Magali Hypolite; Alexandre Montpetit; Pierre Cavailles; Cordelia Bisanz; Marie-France Cesbron-Delauw; Gilbert J Fournié; Rima McLeod
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

Review 4.  Bioactive lipids in Trypanosoma cruzi infection.

Authors:  Fabiana S Machado; Shankar Mukherjee; Louis M Weiss; Herbert B Tanowitz; Anthony W Ashton
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

Review 5.  Modulation of dendritic cell responses by parasites: a common strategy to survive.

Authors:  César A Terrazas; Luis I Terrazas; Lorena Gómez-García
Journal:  J Biomed Biotechnol       Date:  2010-02-24

6.  Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study.

Authors:  Florence Robert-Gangneux; Yvon Sterkers; Hélène Yera; Isabelle Accoceberry; Jean Menotti; Sophie Cassaing; Marie-Pierre Brenier-Pinchart; Christophe Hennequin; Laurence Delhaes; Julie Bonhomme; Isabelle Villena; Emeline Scherer; Frédéric Dalle; Feriel Touafek; Denis Filisetti; Emmanuelle Varlet-Marie; Hervé Pelloux; Patrick Bastien
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

Review 7.  Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii.

Authors:  Jeffrey G Shannon; Robert A Heinzen
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

8.  Vaccination against murine toxoplasmosis using recombinant Toxoplasma gondii SAG3 antigen alone or in combination with Quil A.

Authors:  Young-Ha Lee; Dae-Whan Shin; Jae-Ho Lee; Ho-Woo Nam; Myoung-Hee Ahn
Journal:  Yonsei Med J       Date:  2007-06-30       Impact factor: 2.759

9.  Reduction of Foxp3+ cells by depletion with the PC61 mAb induces mortality in resistant BALB/c mice infected with Toxoplasma gondii.

Authors:  Eda Patricia Tenorio; Jonadab Efraín Olguín; Jacquelina Fernández; Pablo Vieyra; Rafael Saavedra
Journal:  J Biomed Biotechnol       Date:  2009-12-13

10.  Expansion of CD8+CD57+ T Cells in an Immunocompetent Patient with Acute Toxoplasmosis.

Authors:  R García-Muñoz; P Rodríguez-Otero; A Galar; J Merino; J J Beunza; J A Páramo; R Lecumberri
Journal:  Adv Hematol       Date:  2009-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.